Currently, this combination is also approved to treat a variety of BRAF V600E-mutant cancers of different histologies including non-small-cell lung cancer (NSCLC) with the involvement of lymph node(s), locally advanced or metastatic anaplastic thyroid cancer, pediatric low-grade glioma, and any unresectable or metastatic solid tumors with no other satisfactory treatment options. Here, BRAF is linked to thyroid gland undifferentiated (anaplastic) carcinoma.